Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

(MRK) Rises As Market Takes a Dip: Key Facts

In the latest trading session, Merck (MRK) closed at $103.59, marking a +0.13% move from the previous day.

Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit

Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

The latest trading day saw Merck (MRK) settling at $103.88, representing a +0.27% change from its previous close.

Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.

(MRK) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Merck (MRK) closed at $103.60, indicating a +1.4% shift from the previous trading day.

FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.

Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed the most recent trading day at $102.95, moving -1.29% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.

The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy

Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy are part of the Zacks top Analyst Blog.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed the most recent trading day at $103.94, moving -1.38% from the previous trading session.

Mark Vickery headshot

Top Stock Reports for Alphabet, Exxon Mobil & Merck

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca

Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications

The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Merck (MRK) Stock Moves -0.54%: What You Should Know

In the latest trading session, Merck (MRK) closed at $106.73, marking a -0.54% move from the previous day.